http://www.nasdaq.com/article/thora...ll-on-growing-headwinds-analyst-blog-cm413451
The revenue drop was primarily due to the decline in HeartMate II sales, partially offset by continued double-digit revenue growth in the CentriMag business. Third-quarter revenues of $105.8 million also lagged the Zacks Consensus Estimate of $108 million.
The company also slashed its adjusted earnings and revenue guidance owing to lower assumptions for HeartMate II product line on the back of near-term challenges. Thoratec anticipates higher operating expenses in the fourth quarter of 2014 due to accelerated clinical trial activity, targeted commercial investments, and product development project expenses.
- Forums
- ASX - By Stock
- HIN
- Thoratec (THOR) Down
Thoratec (THOR) Down
Featured News
Add HIN (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online